Caricamento...
Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
This study aimed to identify the optimal dose of the endothelin‐1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium retention, as manifested by increase in bodyweight. Data from the RADAR‐JAPAN studies were used, evaluating the effect of 0.75 or 1.25 mg/d...
Salvato in:
| Pubblicato in: | Diabetes Obes Metab |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Blackwell Publishing Ltd
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6055665/ https://ncbi.nlm.nih.gov/pubmed/29603851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13312 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|